Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Bone Marrow Transplantation

Volumn 33, Issue 8, 2004, Pages 789-792

  Fujimaki, K ^a   Taguchi, J ^b   Fujita, H ^b   Hattori, M ^b   Yamazaki, E ^b   Takahashi, N ^b   Fujisawa, S ^a   Kanamori, H ^a   Maruta, A ^b   Ishigatsubo, Y ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Myelodysplastic syndrome; Thiotepa

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THIOTEPA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROBABILITY; REFRACTORY ANEMIA; RISK ASSESSMENT; STOMATITIS; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 11144358658     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704451     Document Type: Article

References (20)

1. Luger S, Sacks N. Bone marrow transplantation for myelodysplastic syndrome - who? when? and which? Bone Marrow Transplant 2002; 30: 199-206.
2. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 (Suppl. 1): S25-S29.
3. Sierra J, Perez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
4. Anderson JE. Allogeneic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation, 2 edn. Blackwell Scientific: Oxford, 1999; pp 872-886.
5. Zecca M, Pession A, Messina C et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 1999; 17: 1838-1846.
6. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
7. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
8. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
9. Castagna L, Weshi EA, Bourhis JH et al. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). Br J Hematol 1998; 103: 284-285.
10. Shiobara S, Nakao S, Ueda M et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769-774.
11. Kroger N, Schetelig J, Zabelina T et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001; 28: 643-647.
12. Rezvani K, Lalancette M, Szydlo R et al. Non-myeloablative stem cell transplant in AML, ALL, and MDS: disappointing outcome for patients with advanced phase disease. Blood 2000; 96 (Suppl): 2061.
13. Locatelli F, Niemeyer C, Angelucci E et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on myelodysplastic syndrome in childhood. J Clin Oncol 1997; 15: 566-573.
14. Ratannatharthorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194-2199.
15. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodisplastic syndrome with advanced disease morphology: a phase II study of buslfan, cyclophosphamide, and total body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
16. Egorin MJ, Snyder SW, Pan SS et al. Cellular transport and accumulation of thiotepa in murine, human, and avian cells. Cancer Res 1989; 49: 5611-5617.
17. Egorin MJ, Snyder SW, Pan SS et al. Cellular transport and accumulation of thiotepa. Semin Oncol 1990; 17: 7-17.
18. Egorin MJ, Snyder SW, Wietharn BE et al. Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells. Cancer Res 1990; 50: 4322-4327.
19. Wolff SN, Herzig RH, Fay JW et al. High-dose N,N′,N″-triethylenthiophosphoramide(thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17 (Suppl. 3): 2-6.
20. Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083-1090.